Extreme Movers: Claude Sonnet 5.5's picks for 2026-10-12
Claude Sonnet 5.5 picked HUM, MRNA, TMUS, CCI, FSLY for a 1-day horizon. Average directional return: +3.13%. Directions called correctly: 80%.
| Experiment | Extreme Movers |
|---|---|
| Model | Claude Sonnet 5.5 |
| Prompt version | extreme-movers-v11 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-09 |
| Measured to | 2026-10-12 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | +3.13% |
| Directions called correctly | 80% |
| Benchmark return | -0.06% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | HUM | up | +0.38% | +0.38% | 58% | +0.44% | Yes |
| 2 | MRNA | down | -5.00% | +5.00% | 57% | +5.06% | Yes |
| 3 | TMUS | up | +2.21% | +2.21% | 55% | +2.27% | Yes |
| 4 | CCI | down | +1.72% | -1.72% | 52% | -1.66% | No |
| 5 | FSLY | down | -9.80% | +9.80% | 48% | +9.86% | Yes |
The model's market view
The S&P 500 rose about 0.6% on Friday October 9 to 7,811.5, near its record high. Friday's biggest large-cap moves came from two catalysts: SpaceX's roughly $8B low-band spectrum purchase, which crushed wireless carriers and lifted tower REITs, and 2027 Medicare Advantage Star Ratings, which helped Humana. Next week brings CPI on Wednesday and bank earnings starting Tuesday. Monday October 12 is a US market session, though the bond market is closed. I treat the speculative, narrative-driven moves (the carrier sell-off, the tower rally, Moderna's index-inclusion run, Fastly's upgrade pop) as reversal candidates. I treat the move with a quantifiable earnings effect (Humana's ratings and bonus payments) as a continuation candidate. All five picks pass the price, market-cap and dollar-volume screens with wide margins. Prices are the Friday October 9 regular-session close, the latest regular-session price available on Saturday October 10, plus after-hours quotes where noted. Average 20-day dollar volume is estimated as the 20-day average share volume times the October 9 close, not an exact average of daily dollar volumes. Treat all of this as a low-confidence directional bet, since single-day outcomes are close to coin flips.
Why each pick
HUM
Humana rose 11.56% on October 9 to a $431.87 close, a 52-week high, after the 2027 Medicare Advantage Star Ratings restored 4 stars to its largest contract (H5216, over 2 million members). The company says 95% of its Medicare Advantage members are now in plans rated 4 stars or higher, which supports quality bonus payments. The catalyst is substantive and quantifiable. Barclays raised its target to $582 and Baird upgraded with a $596 target, both above the price, though the consensus target of about $453 is only about 5% higher. The stock traded at $435.00 after hours (+0.72%), a mildly positive sign. I expect post-ratings drift as analysts revise 2027 and 2028 estimates, so I picked continuation with direction up. Risks: this is a crowded one-day re-rating, so some profit-taking is plausible, and I could not confirm the exact 20-day average dollar volume. The figure is 20-day average shares (1,423,587) times the October 9 close. Price source: October 9 close, 1 day stale, market closed for the weekend.
MRNA
Moderna rose 14.21% on October 9 to a $225.00 close, a new 52-week high, on its Nasdaq-100 inclusion (effective that day, replacing Warner Bros. Discovery). The catalyst is largely technical and speculative: index funds had to buy by the close, and that demand is now spent. The stock is up about 65% in a month and about 700% in a year. RSI is 72, the consensus target of $122.67 is about 45% below the price, and Citi downgraded it to Sell on September 30 for valuation. Net losses are about $3.15B over the last twelve months. Short interest is about 8% of shares outstanding, so a squeeze could continue the run. Given the stretched valuation and the end of forced buying, I picked reversal with direction down. Risks: strong momentum, a heavily shorted name, and possible further cancer-vaccine news flow around the ESMO congress. After-hours was $225.45 (+0.20%). The 20-day average dollar volume is estimated as 17,628,525 shares times the October 9 close rather than an exact figure. Price source: October 9 close, 1 day stale.
TMUS
T-Mobile fell 13.27% on October 9 to a $148.58 close, a 52-week low, after SpaceX agreed to buy about $8B of low-band spectrum from Grain Management for a satellite-plus-terrestrial mobile network. The threat is real but long-dated and speculative: the deal still needs FCC approval, and SpaceX has a long way to go to challenge the three big carriers. The sell-off was also broad (AT&T -9.8%, Verizon -8.7%), which suggests sector-wide overshoot. RSI is 29, the price is about 15% below the 50-day average ($174.85), and fundamentals are unchanged. The company has a 3.15% dividend yield, a 4.5% net buyback yield and a consensus target of $241.71. It reports earnings on October 28. I picked reversal with direction up, a bounce from an oversold level. The stock was $148.75 after hours (+0.11%). Risks: further SpaceX or FCC headlines, and momentum selling after a three-year low. The 20-day average dollar volume is estimated as 5,917,221 shares times the October 9 close, not an exact figure. Price source: October 9 close, 1 day stale.
CCI
Crown Castle rose 15.60% on October 9 to a $79.64 close, the best performer in the S&P 500 that day. The catalyst is largely speculative: SpaceX buying nationwide low-band spectrum is read as a new potential tenant for tower leases, but no lease has been announced and the network is not built. The stock is up about 20% in five days, RSI is 71.75, and the price is above its 50-day average ($73.36). Its earnings report is not until October 21. I picked reversal with direction down, a partial giveback of the one-day jump. Risks: the tower sector (American Tower, SBA) could keep rallying on analyst notes, the dividend yield near 5% attracts buyers, and the consensus target of $94.45 is well above the price. The stock was $79.71 after hours (+0.09%). The 20-day average dollar volume is estimated as 4,253,301 shares times the October 9 close, not an exact figure. Price source: October 9 close, 1 day stale.
FSLY
Fastly rose 15.86% on October 9 to a $29.30 close after Oppenheimer upgraded it to Outperform with a $35 target, citing contract-value growth, security attach rates and early agentic-AI traffic monetization. The catalyst is an analyst opinion rather than new company results, so I classify it as speculative. The stock is up about 240% in 52 weeks and sits above the consensus target of $28.55. It is also well above its 50-day average ($24.85) and, with a 52-week high of $34.82, is near the top of its range after a series of sharp rallies. Its next earnings report is November 4. I picked reversal with direction down. This is the lowest-conviction pick because short interest is about 13.5% of shares outstanding, so a squeeze could extend the gain. After hours it traded at $29.40 (+0.34%). The 20-day average dollar volume is estimated as 8,198,155 shares times the October 9 close, not an exact figure. Price source: October 9 close, 1 day stale.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| Grok 4.5 | CCI, MRNA, HUM, TMUS, T | -1.30% | 40% |
| Muse Spark 1.1 | LITE, CIEN, HUM, T, FSLY | -1.63% | 60% |
| GPT-6 | TMUS, HUM, CCI, AMT, ASTS | +0.33% | 60% |
| Perplexity | HUM, TMUS, T, CCI, ASTS | +0.26% | 60% |
| Gemini 1.5 Pro | CCI, HUM, MRNA, TMUS, DDOG | -0.62% | 60% |
| DeepSeek | FSLY, NVAX, TMUS, HUM, ALHC | -3.63% | 40% |
Written up on ForecastNest Insights: Extreme Movers: Claude Sonnet 5.5's picks for 2026-10-12.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.